A Bioactive *seco*-Rosane Diterpenoid from *Vellozia candida*

Ligia M. M. Valente,[†,‡,§] A. A. Leslie Gunatilaka,[‡,∥] David G. I. Kingston,[*,‡] Maria L. Patitucci,[§] and Angelo C. Pinto[*,§]

Department of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0212, and Instituto de Química, Universidade Federal do Rio de Janeiro, Centro de Tecnologia, Bloco A, Cidade Universitária, Ilha do Fundão, 21910-240, Rio de Janeiro, RJ, Brazil

Received October 24, 1996[⊗]

Bioassay-directed fractionation of the bioactive alcoholic extracts of *Vellozia candida* yielded a new 6,7-*seco*-rosane diterpenoid, candidalactone (**1**), which showed moderate toxicity toward DNA repair-deficient mutants of *Saccharomyces cerevisiae.* Another new but inactive rosane diterpenoid, candidenodiol (**3**), was also obtained.

Vellozia candida Mikan (Velloziaceae)[1] inhabits the coastal mountains of Rio de Janeiro. Previous studies on this plant have afforded several rosane diterpenoids including epoxycorcovadin, epoxyvellozin,[2,3] and vellozi-olide,[4] a diterpenoid with a novel carbon skeleton. In our continuing search for potential anticancer agents utilizing a mechanism-based bioassay,[5,6] and continuing our phytochemical studies on Velloziaceae,[2−4] we have investigated alcoholic extracts of *V. candida.* In this paper, we report the isolation of a new bioactive 6,7-*seco*-rosane diterpenoid, candidalactone (**1**), and a new but inactive rosane diterpenoid, candidenodiol (**3**).



The dried and powdered whole plant of *V. candida* was sequentially extracted with hexane, EtOH, and MeOH. Of these, the latter two extracts showed moderate activity in our mechanism-based bioassay[5,7] and were subjected to bioassay-guided fractionation involving solvent−solvent partition, Sephadex LH-20 gel filtration, Si gel CC, and RP-HPLC, as appropriate, to afford the two new compounds **1** and **3**, of which **1** was found to be moderately bioactive.

Candidalactone (**1**), $C_{20}H_{28}O_4$ (HREIMS), showed the presence of four methyl groups (δ 1.09 s, 1.17 s, 1.24 s, 1.32 s), a vinyl group [δ 5.71 dd (J = 17.9, 10.9 Hz), 5.17 d (J = 10.9 Hz)], all attached to quaternary carbons, two allylic protons (δ 2.21−2.26 m), a proton on an oxygenated carbon [δ 3.94 dd (J = 12.8, 3.7 Hz)], and a proton on a carbon bearing a CO_2H group [δ 2.51 dd (J = 12.2, 3.2 Hz)] in its ^{1}H-NMR spectrum. The presence of a carboxylic acid function and an $\alpha\beta$-unsaturated lactone moiety in **1** were inferred from its IR spectrum. The ^{13}C-NMR spectrum of candidalactone (**1**) analyzed with the help of its DEPT spectrum showed a lactone carbonyl (δ 163.4), a carboxylic acid carbonyl (δ 179.2), two tetrasubstituted sp[2] carbons (δ 131.7, 159.5), three tetrasubstituted sp[3] carbons (δ 33.3, 36.8, 41.9), and an oxygenated methine carbon (δ 77.4) in addition to the four methyl groups (δ 11.1, 27.1, 28.7, 31.0) and the vinyl group [δ 113.9 (CH_2) and 144.2 (CH)]. These data along with the knowledge of the presence of rosane diterpenoids in this plant species[2−4] suggested the presence of a modified rosane carbon skeleton in **1**. It was also apparent that the C_6−C_7 bond has undergone an oxidative cleavage and that one of the resulting CO_2H groups (at C-5) has formed a lactone with the OH group at C-11 usually present in *Vellozia* diterpenoids. The MS of **1** showed fragment ions at m/z 179 and 135, assignable to the fragments shown in Scheme 1, further suggesting that it has a 6,7-*seco*-rosane skeleton. The formation of the methyl ester **2** on treatment of **1** with CH_2N_2 confirmed the presence of a CO_2H group in candidalactone, and this was located at C-8 on the basis of biogenetic arguments. ^{1}H- and ^{13}C-NMR assignments of candidalactone (**1**) (see Table 1) were made by comparison with those data reported for rosane diterpenoids[3] and with the help of COSY-45 and HETCOR spectra, and these assignments confirmed the location of the carboxyl group at C-8.

Scheme 1. Proposed MS Fragmentation for Candidalactone (**1**)



The stereochemical assignments at C-8, C-9, C-11, and C-13 were made by the application of ^{1}H-NMR, ^{13}C-NMR, COSY-45, HETCOR, and NOESY spectroscopy. The ^{1}H-NMR signal for H-8 at δ 2.51, assigned on the basis of its chemical shift, appeared as a dd (J = 12.2,

* To whom correspondence should be addressed.
† Visiting CNPq Fellow at Virginia Polytechnic Institute and State University, 1992−93. Current address: Instituto de Química, Universidade Federal do Rio de Janeiro, Centro de Tecnologia, Bloco A, Cidade Universitária, Ilha do Fundão, 21910-240, Rio de Janeiro, RJ, Brazil.
‡ Virginia Polytechnic Institute and State University.
§ Universidade Federal do Rio de Janeiro.
∥ Current address: Bioresources Research Faculty, The University of Arizona, 250 East Valencia Road, Tucson, AZ 85706.
⊗ Abstract published in *Advance ACS Abstracts,* April 15, 1997.

S0163-3864(96)00695-7 CCC: $14.00 © 1997 American Chemical Society and American Society of Pharmacognosy



Figure 1. NOE interactions for compound **1**.

3.2 Hz), suggesting it to be axial. Consequently, the CO_2H function on C-8 must have an equatorial orientation. On the basis of similar arguments, the attachment of the lactone oxygen at C-11 was determined to be equatorial. An upfield shift of the ^{13}C-NMR signal of the C-20 methyl group [δ_C 11.1 as opposed to δ_C >12.0 for related rosane diterpenoids][3,8] suggested that it suffered a γ-gauche shielding effect from the C-8-CO_2H. In the NOESY spectrum of **1** cross peaks were observed between H-8 and H-11, H-8 and H-16a, and H-11 and H-16a (Figure 1), suggesting that these protons lie on the same side of the *seco*-rosane carbon skeleton. An examination of a computer-generated model revealed that these protons lie in close proximity to one another. From the foregoing evidence, candidalactone was identified as 6,7-*seco*-rosane-5(10),15-dien-7-oic acid 6,11-carbolactone (**1**). A compound that was shown to be identical with candidalactone also occurred in the hexane extract of *V. candida*, but no bioactivity data were obtained for this sample.[9]

The ^1H- and ^{13}C-NMR spectral data (Table 1) of candidenodiol (**3**), $C_{20}H_{30}O_3$ (HREIMS), suggested it to be a rosane diterpenoid. Its UV and IR spectra were indicative of the presence of an enone moiety, which was confirmed from its ^1H- and ^{13}C-NMR spectra, which had signals at δ_H 6.20 (s), and δ_C 200.4, 166.4, and 123.7. The ^1H- and ^{13}C-NMR spectral data, in addition to the presence of signals due to four methyl groups and a vinyl group, all on quaternary carbons usually found in the rosane skeleton, indicated the presence of secondary [δ_H 4.36 dd (J = 11.8, 3.9 Hz); δ_C 67.8 (d)] and

Scheme 2. Proposed MS Fragmentation for Candidenodiol (**3**)



tertiary [δ_C 76.3 (s)] carbinol carbons. Location of the enone moiety and the two hydroxy groups, accounting for all three oxygen atoms present in the molecule, was achieved by analysis of COSY-45, HMBC, and mass spectra as described below.

The olefinic H of the enone moiety appeared as a sharp singlet, and no correlations were observed in the COSY-45 spectrum. The presence of significant fragments at m/z 203 and 166 in the MS of **3** (Scheme 2) suggested the possible location of the enone moiety in ring B; the latter fragment also indicated the presence of an OH group in ring A of **3**. The shift of the base peak from m/z 203 to 207 (fragment **A** in Scheme 2) in the MS of the tetradeuterated analog **4**[10] further supported the proposed MS fragmentation for **3**. The HMBC correlation observed between the enone olefinic H and the oxygenated quaternary carbon at δ_C 76.3 located the OH group at C-10. An HMBC correlation was also observed between this carbon and the protons of the Me group at δ_H 0.86; the latter signal correlated

Table 1. ^1H- and ^{13}C-NMR Spectral Data for Compounds **1** and **3** (δ in ppm, $CDCl_3$)

	1		**3**	
position	δH (m, J (Hz))[a]	δC[b,c]	δH (m, J (Hz))[a]	δC[b,c]
1[d]	2.21–2.26 (m)	26.1 (CH_2)	2.53 (bddd, 15.4, 11.2, 2.9)	34.8 (CH_2)
2[d]	1.66–1.74 (m)	18.4 (CH_2)	1.51–1.56 (m)	17.2 (CH_2)
3α	1.37 (dd, 13.9, 2.9)	39.6 (CH_2)	1.36–1.46 (m)[e]	39.2 (CH_2)
3β	1.47–1.53 (m)		1.51–1.62 (m)	
4		33.3 (C)		36.6 (C)
5		131.7 (C)		166.4 (C)
6		163.4 (C)	6.20 (s)	123.7 (CH)
7		179.2 (C)		200.4 (C)
8	2.51 (dd, 12.2, 3.2)	43.7 (CH)	2.88 (dd, 12.3, 3.6)	44.7 (CH)
9		41.9 (C)		47.8 (C)
10		159.5 (C)		76.3 (C)
11	3.94 (dd, 12.8, 3.7)	77.4 (CH)	4.36 (dd, 11.8, 3.9)	67.8 (CH)
12α	1.69 (t, 12.8)	37.8 (CH_2)	1.77 (ddd, 14.2, 3.9, 2.9)	43.4 (CH_2)
12β	1.86–1.92 (m)		1.33–1.46 (m)[e]	
13		36.8 (C)		36.7 (C)
14α	1.77 (t, 13.6)	37.1 (CH_2)	2.03 (ddd, 14.2, 3.6, 2.9)	31.5 (CH_2)
14β	1.86–1.92 (m)		1.33 (dd, 14.2, 12.3)	
15	5.71 (dd, 17.9, 10.9)	144.2 (CH)	5.72 (dd, 17.6, 11.0)	145.2 (CH)
16a	5.11 (d, 17.9)	113.9 (CH_2)	5.04 (dd, 17.6, 0.8)	113.0 (CH_2)
16b	5.17 (d, 10.9)		5.07 (dd, 11.0, 0.8)	
17	1.09 (s)	31.0 (CH_3)	1.04 (s)	31.0 (CH_3)
18	1.32 (s)	27.1 (CH_3)	1.30 (s)	31.1 (CH_3)[f]
19	1.24 (s)	28.7 (CH_3)	1.16 (s)	31.3 (CH_3)[f]
20	1.17 (s)	11.1 (CH_3)	0.86 (s)	9.6 (CH_3)

[a] Measured at 400 MHz. [b] Measured at 100.57 MHz. [c] Type of carbon (in parentheses) determined by a DEPT experiment. [d] Signal due to one of the two protons at this position: the remaining proton could not be assigned. [e] Overlapping signals. [f] Interchangeable.



Figure 2. HMBC connectivitied (^{1}H → ^{13}C) of compound **3**.

with the carbinol carbon at δ_C 67.8, thus locating the secondary OH function at C-11. The proton signal (dd) at δ 2.88 showed correlations to the quaternary carbon at δ_C 47.8. Thus, the ^{1}H-NMR signal at δ_H 2.88 was assigned to H-8 and the ^{13}C-NMR signal at δ 47.8 to C-9. These and other significant HMBC correlations for **3** are shown in Figure 2. The coupling pattern of the ^{1}H-NMR signal at δ_H 4.36 (dd, J = 11.8, 3.9 Hz), which showed a HETCOR correlation with δ_C 67.8 (see above), indicated that this proton should be axially oriented. The chemical shift of the Me-20 (δ_C 9.6) suggested that it is subjected to a γ-gauche effect from the OH group at C-11 and, consequently must be in an axial orientation. The coupling pattern observed for H-8 at δ_H 2.88 (dd, J = 12.3 and 3.6 Hz) suggested it to be axially oriented. Thus, the B,C ring junction of **3** must be *trans*.

The absolute stereochemistry of candidenodiol (**3**) was derived from an analysis of its CD spectrum in MeOH. As for other αβ-unsaturated 6-membered ring ketones,[11] the CD spectrum of **3** showed two bands of lowest energy; n → π^* at 332 nm and $\pi \rightarrow \pi^*$ at 262 nm with positive and negative Cotton effects, respectively. Application of helicity rules[11] indicated the absolute configuration of candidenodiol to be as shown in structure **3** leading to its identification as 10(*S*),11(*R*)-dihydroxy-5(6),15-rosanedien-7-one.

Candidalactone (**1**) exhibited moderate but selective activity in our mechanism-based yeast bioassay for DNA-damaging agents[5-7] with the following IC_{12} values: RS 322YK (*rad* 52Y), 87 μg/mL; RS 188N (RAD+) >200 μg/mL. These results indicated that candidalactone represents the major bioactive compound in the crude extract of *V. candida*.

Experimental Section

General Experimental Procedures. UV spectra were taken in MeOH on a Beckman DU-50 spectrophotometer. Optical rotations were determined with a Perkin-Elmer Model 241 polarimeter in $CHCl_3$ solutions. NMR spectra (δ ppm, J in Hz) were obtained on a Varian Unity 400 spectrometer (400 MHz) for compounds **1** and **3**, and on a Bruker WM-400 (400 MHz) for compound **2** using TMS as internal standard. EIMS were obtained using a VG Quattro instrument at 70 eV. Column chromatography (CC) employed Si gel 60 (230–400 mesh) and Sephadex LH-20 (25–100 μM). TLC and PTLC were performed by using precoated Si gel 60 F_{254} and Si gel GF 1000 μM plates, respectively, and detection was accomplished by UV_{254} irradiation and by spraying with ceric sulfate/H_2SO_4 followed by heating. HPLC separation of compound **3** was carried out on a Whatman Partisil 5 μm column with a Waters 990 Series photodiode array detector at 248 nm.

Plant Material. *V. candida* was collected in the Corcovado mountain, Rio de Janeiro, RJ, Brazil in February 1977. A voucher specimen is deposited at the Departamento de Botânica of the Universidade de São Paulo, São Paulo, SP, Brazil.

Biological Assays. The bioassays using DNA repair deficient mutants of *Saccharomyces cerevisiae* were performed as previously described.[6] The IC_{12} values refer to the concentration in μg/mL required to produce a zone of inhibition of 12 mm diameter around a 100 μL well during a 48 h incubation period at 32 °C.

Extraction and Isolation. The dried and powdered whole plant of *V. candida* (2.3 kg) was sequentially extracted with hexane, EtOH, and MeOH. Evaporation yielded hexane (79.3 g), EtOH (12.5 g), and MeOH (6.0 g) extracts. A portion of the EtOH extract (3.1 g) was partitioned between *n*-BuOH and water. The bioactive *n*-BuOH fraction was then fractionated between hexane and 80% aqueous MeOH. Water was then added to the bioactive aqueous MeOH fraction to give 60% aqueous MeOH, and this fraction was extracted thoroughly with $CHCl_3$ to yield 1.2 g of the bioactive $CHCl_3$ fraction. The $CHCl_3$ fraction was subjected to gel permeation chromatography on Sephadex LH-20, eluting initially with hexane–CH_2Cl_2 (1:4), followed by CH_2Cl_2–acetone (2:3), CH_2Cl_2–acetone (1:4), and finally with MeOH. A portion of the bioactive fraction (198 mg) from the hexane–CH_2Cl_2 (1:4) fraction (497.6 mg) of the above Sephadex column was submitted to Si gel CC using a gradient solvent system from 2% *i*-PrOH in $CHCl_3$ to MeOH yielding 60 fractions. The bioactive fractions (nos. 25–33; 51.3 mg) were combined and rechromatographed on Si gel CC using 5% *i*-PrOH in $CHCl_3$, yielding 42 fractions. Fractions 21–36 were found to be bioactive. On the basis of their TLC behavior, two combined fractions (nos. 21–29; 8.7 mg and 30–36; 27.9 mg) were obtained, and these were separately submitted to Si gel CC. Compound **1** (2.5 mg) was isolated from 6.0 mg of fractions 21–29 on separation by Si gel CC using hexane–*i*-PrOH (7:1) followed by hexane–*i*-PrOH (4:1) and then crystallization using hexane–EtOAc (5:1).

A portion of the MeOH extract of *V. candida* (2.89 g) was partitioned as for the EtOH extract (see above). The bioactive $CHCl_3$ fraction (1.32 g) was submitted to Sephadex LH-20 gel permeation chromatography eluting initially with hexane, followed by 5%, 30%, 50%, and 80% CH_2Cl_2 in hexane, 10% and 80% acetone in CH_2Cl_2, and finally with MeOH. The bioactive 50% CH_2Cl_2 in hexane fraction (429.6 mg) was chromatographed on a Si gel CC using hexane–*i*-PrOH (9:1) to MeOH, yielding 49 fractions. A portion of the bioactive fractions (nos. 13–36; 42.5 mg) was submitted to PTLC separation on Si gel using 6% *i*-PrOH in $CHCl_3$ containing 1% of AcOH as the eluant, yielding 6.3 mg of a solid that by successive crystallization from hexane–EtOAc (5:1) yielded 1.1 mg of compound **1**. A portion (24.3 mg) of the combined inactive fraction (54.9 mg) was submitted to Si gel HPLC using 2% *i*-PrOH in $CHCl_3$ as the mobile phase, yielding compound **3** (8.4 mg).

Candidalactone (1): colorless crystals [hexane–AcOEt (5:1)]; mp 176–177 °C; UV λ_{max} ((MeOH) (log ϵ) 231 (3.85) nm; $[\alpha]^{24}_D$ +69.4 (c = 2.5, $CHCl_3$); IR ν_{max} (KBr) 3500–3000 br, 1715, 1700, 1631, 1404, 1276, 1236, 1078, 997, 898 cm^{-1}; HREIMS found [M$^+$] 332.1970, $C_{20}H_{28}O_4$ requires 332.1988; ^{1}H- and ^{13}C-NMR spectra, see Table 1; EIMS m/z (rel int) 332 [M$^+$]

(100), 317 (37), 179 (10), 135 (45), 121 (21), 107 (28), 43 (41), 41 (42).

Candidalactone Methyl Ester (2). Candidalactone (70.0 mg), isolated from the hexane extract,[8] was dissolved in Et_2O (2 mL), and a saturated ethereal solution of CH_2N_2 was added. After the excess CH_2N_2 was destroyed with AcOH, the solvent was evaporated, and the solid obtained was crystallized from hexane–AcOEt (9:1), yielding **2** (71.6 mg): $[\alpha]^{24}_{D}$ +86.8 (c = 0.95, $CHCl_3$); IR ν_{max} (KBr) 2950, 1720, 1704, 1630, 1429, 1355, 1264, 1211, 1164, 1067, 1018, 929 cm^{-1}; ^1H-NMR ($CDCl_3$, 400 MHz) 1.05 (H_3-17, s), 1.15 (H_3-20, s), 1.22 (H_3-19, s), 1.31 (H_3-18, s), 2.48 (H-8, dd, J = 11.0, 5.0 Hz), 3.68 (3H-$OCOCH_3$, s), 3.92 (H-11, dd, J = 13.0, 4.0 Hz), 5.08 (H-16a, d, J = 18.0 Hz), 5.13 (H-16b, d, J = 11.0 Hz), 5.69 (H-15, dd, J = 18.0, 11.0 Hz); ^{13}C-NMR ($CDCl_3$, 100.57 MHz) 11.20 (C-20), 18.40 (C-2), 25.60 (C-1), 27.00 (C-18), 28.70 (C-19), 30.90 (C-17), 33.20 (C-4), 36.70 (C-12), 37.00 (C-13), 37.60 (C-12), 39.60 (C-3), 41.90 (C-9), 43.60 (C-8), 51.90 (OCO*C*H_3), 77.20 (C-11), 113.50 (C-16), 131.40 (C-5), 144.20 (C-15), 159.60 (C-10), 163.20 (C-6), 175.10 (C-7); EIMS m/z (rel int) 346 $[M^+]$ (100), 331 (20), 135 (37), 121 (13), 107 (18), 43 (15), 41 (28).

Candidenodiol (3): oil; UV λ_{max} ((MeOH) (log ϵ) 240 (3.4) and 308 (2.9) nm; $[\alpha]^{24}_{D}$ +58.4 (c = 4.5, $CHCl_3$); IR ν_{max} (film) 3450, 1660 cm^{-1}; HREIMS $[M^+]$ 318.2195, $C_{20}H_{30}O_3$ requires 318.2194; ^1H- and ^{13}C-NMR data, see Table 1; EIMS m/z (rel int) 318 $[M^+]$ (36), 300 (33), 285 (45), 249 (24), 229 (26), 203 (100), 193 (76), 179 (26), 166 (94), 151 (76), 139 (83), 135 (38), 123 (19), 109 (28).

Acknowledgment. This work was supported by the National Cancer Institute under a National Cooperative Drug Discovery Group awarded to the University of Virginia (Dr. S. M. Hecht, Principal Investigator; 1-UO1-CA 50771). One of us (L.M.M.V.) thanks the Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPq (Brazil) for fellowship support and the Programa de Capacitação Docente da Universidade do Estado do Rio de Janeiro-PROCAD/UERJ (Brazil) for additional support. The authors also thank Dr. Nanuza L. de Menezes from the Departamento de Botânica of the Universidade de São Paulo (Brazil) for the identification of the plant material, Ms. Nina J. Baj (VPI & SU) for assistance with yeast bioassay, Mr. Thomas E. Glass (VPI & SU) for some 2D NMR spectra, and Mr. Kim Harich (VPI & SU) for MS.

References and Notes

(1) Menezes, N. L. de. In *Petaloid Monocotyledons: Horticultural and Botanical Research*; Brickell, C. D., Cutler, D. F., Gregory, M., Eds.; Linnean Society Symposium Series, Vol. 9; Academic Press: London, 1980; pp 117–139.
(2) Pinto, A. C.; Scofield, T. C. V.; Braz Filho, R. *Tetrahedron Lett.* **1983**, *24*, 5043–5046.
(3) Pinto, A. C.; Garcez, W. S.; Ficara, M. L. G.; Vasconcelos, T. C.; Pereira, A. L.; Gomes, L. N. L. F.; Frechiani, M. C.; Patitucci, M. L. *Anais Acad. Bras. Ciênc.* **1982**, 103–105.
(4) Pinto, A. C.; Gonçalves, M. L. A.; Braz Filho, R.; Neszmelyi, A; Luckacs, G. *J. Chem. Soc., Chem. Commun.* **1982**, 293–295.
(5) Gunatilaka, A. A. L.; Kingston, D. G. I.; Johnson, R. K. *Pure Appl. Chem.* **1994**, *66*, 2219–2222.
(6) Gunatilaka, A. A. L.; Samaranayake, G.; Kingston, D. G. I.; Hofmann, G.; Johnson, R. K. *J. Nat. Prod.* **1992**, *55*, 1648–1654.
(7) Johnson, R. K.; Bartus, H. F.; Hofmann, G. A.; Bartus, J. O.; Mong, S. M.; Faucette, L. F.; McCabe, F. L.; Chan, J. A.; Mirabelli, C. K. In *In Vitro and In Vivo Models for Detection of New Antitumor Drugs*; Hanka, L. J., Kondo, T., White, R. J., Eds.; Organizing Conmittee of the 14th International Congress of Chemotherapy: Kyoto, 1986; pp 15–26.
(8) Garcia-Alvarez, M. C.; Rodriguez, B.; Valverde, S.; Fraga, B. M.; Gonzalez, A. G. *Phytochemistry* **1981**, *20*, 167–169.
(9) Patitucci, M. L. Constituentes Quimicos de Vellozia leptopetala. MS Thesis, Universidade Federal de Rio de Janeiro, Rio de Janeiro, RJ, Brazil, 1983, p 96.
(10) The tetradeuterated analog **4** was prepared by refluxing 1,10-dehydrocandidenodiol (10 mg; previously isolated from *V. candida* hexane extract) with NaOD (200 mg) in CD_3OD–D_2O (1:1) for 24 h; for details of isolation of 1,10-dehydrocandidenodiol, see: Ficara, M. L. G. MS Thesis, Universidade Federal de Rio de Janeiro, Rio de Janeiro, RJ, Brazil, 1980, p 27.
(11) Burnett, R. D.; Kirk, D. N. *J. Chem. Soc., Perkin Trans. 1* **1981**, 1460–1468.

NP960695A